Jinwon Life Sciences Signs Clinical Trial Agreement for COVID-19 Vaccine with Korea University Guro Hospital
Signing ceremony for the COVID-19 vaccine (GLS-5310) clinical trial contract. (From left) Han Seung-gyu, Director of Korea University Guro Hospital; Kim Woo-joo, Professor of Infectious Diseases; Cho Byung-moon, Executive Director of GeneOne Life Science; Jung Moon-seop, Head of Research Institute. / Photo by GeneOne Life Science
View original image[Asia Economy Reporter Jang Hyowon] On the 21st, GeneOne Life Science announced that on the 18th, it signed a contract with Korea University Guro Hospital to conduct a Phase 1/2a clinical trial of GLS-5310, a novel coronavirus disease (COVID-19) preventive vaccine.
GeneOne Life Science's GLS-5310 differentiates itself from other COVID-19 vaccines under development domestically and internationally by including not only the spike antigen but also an additional antigen involved in the COVID-19 infection and disease progression process, thereby enhancing protection against viral mutations and improving preventive efficacy. The vaccine also adopts a highly convenient administration method, preparing for large-scale vaccination.
A company representative stated, “In the Phase 1 clinical trial, the safety, optimal dosage, and dosing interval of GLS-5310 will be selected in 45 healthy adults. Subsequently, a Phase 2a clinical trial will be conducted with 300 healthy adults in a placebo-controlled, double-blind manner to evaluate the safety and immunogenicity of GLS-5310 at five clinical institutions, including Korea University Guro Hospital.”
Due to COVID-19 restrictions, only a limited number of people attended the contract signing ceremony, including Han Seung-gyu, director of Korea University Guro Hospital, Kim Woo-joo, professor of infectious diseases and clinical trial principal investigator, and company representatives.
Park Young-geun, CEO of GeneOne Life Science, expressed gratitude, saying, “We thank the staff of Korea University Guro Hospital for their cooperation in swiftly concluding the clinical trial contract following the Ministry of Food and Drug Safety’s clinical approval on the 4th. Amid the severe domestic COVID-19 situation, we will do our best to ensure not only rapid clinical development but also the mass production and large-scale vaccination of the vaccine, so that the COVID-19 vaccine can be supplied domestically as soon as possible.”
Hot Picks Today
There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- Court Halts Kim Bomseok's Designation as Coupang Owner...Suspends Fair Trade Commission's Order
- Cerebras Soars 70% on IPO Debut: Is Nvidia's Reign Ending as a New AI Semiconductor Power Emerges?
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Kim Woo-joo, professor of infectious diseases at Korea University Guro Hospital and principal investigator of the clinical trial, said, “It is an honor to lead the vaccine clinical trial. We look forward to safe and effective clinical results of the GLS-5310 vaccine and will do our utmost to help Korea secure vaccine sovereignty in COVID-19 vaccination.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
